68Ga-PSMA PET/CT for Ra223 Assessment
- Conditions
- Metastatic Prostate Cancer
- Registration Number
- NCT04951817
- Lead Sponsor
- Chang Gung Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 52
Inclusion Criteria:<br><br> 1. Males with 40-85 years of age and life expectancy more than 3 months<br><br> 2. Patient was diagnosed as mCRPC, and meet the standard criteria of using<br> 223Ra-dichloride (symptomatic bone metastasis, at least two bone metastasis sites,<br> no visceral organ metastasis)<br><br> 3. Willing to sign the informed consent<br><br> 4. ECOG performance status Grade 0-2<br><br>Exclusion Criteria:<br><br> 1. Unable to tolerate the PET/CT scan, such as those with claustrophobia, unable to lie<br> still, consciousness unclear, vital sign unstable.<br><br> 2. With renal impairment (glomerular filtration rate lower than 30 ml/min/1.73 m2), and<br> allergy to medium contrast.<br><br> 3. Significant abnormal lab data (AST or ALT more than three times of normal value),<br> and high risk to conduct examination after evaluations of PI.<br><br> 4. Patient had previous other malignancy history<br><br> 5. Patient experiences grade 3-4 neutropenia (neutrophil counts less than 1000/uL) or<br> thrombocytopenia (platelet counts less than 50x103/uL) lasting > 14 days
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of lesion detection number by PET imaging
- Secondary Outcome Measures
Name Time Method